{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:29:10Z","timestamp":1764858550945},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Huazhong Univ. Sci. Technol. [Med. Sci.]"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1007\/s11596-010-0559-5","type":"journal-article","created":{"date-parts":[[2010,11,9]],"date-time":"2010-11-09T12:15:58Z","timestamp":1289304958000},"page":"652-658","source":"Crossref","is-referenced-by-count":17,"title":["A meta-analysis of mood stabilizers for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Haibing","family":"Xiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenggang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihou","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,10]]},"reference":[{"issue":"10","key":"559_CR1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1212\/WNL.54.10.1965","volume":"54","author":"J.S. Paulsen","year":"2000","unstructured":"Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology, 2000,54(10):1965\u20131971","journal-title":"Neurology"},{"issue":"1","key":"559_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/appi.neuropsych.14.1.11","volume":"14","author":"R.E. Tractenberg","year":"2002","unstructured":"Tractenberg RE, Weiner MF, Thal LJ. Estimating the prevalence of agitation in community-dwelling persons with Alzheimer\u2019s disease. J Neuropsychiatry Clin Neurosci, 2002,14(1):11\u201318","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"559_CR3","unstructured":"Alexopoulos GS, Silver JM, Kahn DA, et al. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia. Postgrad Med, 1998,Spec No:1-88"},{"issue":"Suppl2","key":"559_CR4","first-page":"5","volume":"65","author":"G.S. Alexopoulos","year":"2004","unstructured":"Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry, 2004,65(Suppl 2):5\u2013104","journal-title":"J Clin Psychiatry"},{"key":"559_CR5","doi-asserted-by":"crossref","unstructured":"Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev, 2009,(3):CD003945","DOI":"10.1002\/14651858.CD003945.pub3"},{"issue":"1","key":"559_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"A.R. Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary. Control Clin Trials, 1996,17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"1","key":"559_CR7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00019442-200102000-00009","volume":"9","author":"A.P. Porsteinsson","year":"2001","unstructured":"Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001,9(1):58\u201366","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"559_CR8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gps.653","volume":"17","author":"R.C. Sival","year":"2002","unstructured":"Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementi-A randomized placebo controlled clinical trial. Int J Geriatr Psychiatry, 2002,17(6):579\u2013585","journal-title":"Int J Geriatr Psychiatry"},{"key":"559_CR9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0011-393X(01)80042-4","volume":"62","author":"P.N. Tariot","year":"2001","unstructured":"Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Rev, 2001,62:51\u201367","journal-title":"Curr Ther Rev"},{"issue":"2","key":"559_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000199236","volume":"27","author":"O.H. Sommer","year":"2009","unstructured":"Sommer OH, Aga O, Cvancarova M, et al. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia. Dement Geriatr Cogn Disord, 2009,27(2):155\u2013163","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"559_CR11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1176\/ajp.155.1.54","volume":"155","author":"P.N. Tariot","year":"1998","unstructured":"Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry, 1998,155(1):54\u201361","journal-title":"Am J Psychiatry"},{"issue":"11","key":"559_CR12","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1532-5415.1994.tb06982.x","volume":"42","author":"P.N. Tariot","year":"1994","unstructured":"Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc, 1994, 42(11):1160\u20131166","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"559_CR13","first-page":"354","volume":"56","author":"M.R. Lemke","year":"1995","unstructured":"Lemke MR. Effect of carbamazepine on agitation in Alzheimer\u2019s inpatients refractory to neuroleptics. J Clin Psychiatry, 1995,56(8):354\u2013357","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"559_CR14","first-page":"115","volume":"51","author":"R.P. Gleason","year":"1990","unstructured":"Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer\u2019s outpatients refractory to neuroleptics. J Clin Psychiatry, 1990,51(3):115\u2013118","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"559_CR15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","volume":"70","author":"H. Hampel","year":"2009","unstructured":"Hampel H, Ewers M, B\u00fcrger K, et al. Lithium trial in Alzheimer\u2019s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry, 2009,70(6):922\u2013931","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"559_CR16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3233\/JAD-2009-1004","volume":"16","author":"T. Leyhe","year":"2009","unstructured":"Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer\u2019s disease. J Alzheimers Dis, 2009,16(3):649\u2013656","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"559_CR17","doi-asserted-by":"crossref","first-page":"11611","DOI":"10.1159\/000097757","volume":"23","author":"N. Herrmann","year":"2007","unstructured":"Herrmann N, Lanct\u00f4t KL, Rothenburg LS, et al. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord, 2007,23(2):11611\u201311619","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"559_CR18","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/gps.1964","volume":"23","author":"A. Macdonald","year":"2008","unstructured":"Macdonald A, Briggs K, Poppe M, et al. A feasibility and tolerability study of lithium in Alzheimer\u2019s disease. Int J Geriatr Psychiatry, 2008,23(7):704\u2013711","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"559_CR19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00019442-200111000-00008","volume":"9","author":"J.T. Olin","year":"2001","unstructured":"Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry, 2001,9(4):400\u2013405","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"559_CR20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/156720505774932205","volume":"2","author":"L.A. Profenno","year":"2005","unstructured":"Profenno LA, Jakimovich L, Holt CJ, et al. A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer\u2019s disease. Curr Alzheimer Res, 2005,2(5):553\u2013558","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"559_CR21","first-page":"942","volume":"13","author":"P.N. Tariot","year":"2005","unstructured":"Tariot PN, Raman R, Jakimovich L, et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry, 2005,13(11):942\u2013949","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"559_CR22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G. Mckhann","year":"1984","unstructured":"Mckhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease. Neurology, 1984,34(7):939\u2013944","journal-title":"Neurology"},{"issue":"12","key":"559_CR23","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"J.L. Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, et al. The Neuropsyc iatric Inventory: comprehensive assessment of psychopat hology in dementia. Neurology, 1994,44(12):2308\u20132314","journal-title":"Neurology"},{"issue":"15","key":"559_CR24","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"L.S. Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005,294(15):1934\u20131943","journal-title":"JAMA"},{"issue":"2","key":"559_CR25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00023210-200519020-00001","volume":"19","author":"N. Herrmann","year":"2005","unstructured":"Herrmann N, Lanct\u00f4t KL. Do atypical antipsychotics cause stroke? CNS Drugs, 2005,19(2):91\u2013103","journal-title":"CNS Drugs"},{"issue":"12","key":"559_CR26","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0169-409X(02)00153-9","volume":"54","author":"P.N. Tariot","year":"2002","unstructured":"Tariot PN, Loy R, Ryan JM, et al. Mood stabilizers in Alzheimer\u2019s disease: symptomatic and neuroprotective rationales. Adv Drug Deliv Rev, 2002,54(12):1567\u20131577","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"559_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","volume":"58","author":"W. L\u00f6scher","year":"1999","unstructured":"L\u00f6scher W. Valproate: a reappraisal of its pharmacody namic properties and mechanisms of action. Prog Neurobiol, 1999,58(1):31\u201359","journal-title":"Prog Neurobiol"},{"issue":"2","key":"559_CR28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0197-4580(94)00150-2","volume":"16","author":"R.J. Mark","year":"1995","unstructured":"Mark RJ, Ashford JW, Goodman Y, et al. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging, 1995,16(2):187\u2013198","journal-title":"Neurobiol Aging"},{"key":"559_CR29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0079-6123(08)60453-7","volume":"116","author":"N.B. Farber","year":"1998","unstructured":"Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer\u2019s disease. Prog Brain Res, 1998,116:421\u2013437","journal-title":"Prog Brain Res"},{"issue":"6","key":"559_CR30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00702-004-0221-0","volume":"112","author":"C.X. Gong","year":"2005","unstructured":"Gong CX, Liu F, Grundke-Iqbal I, et al. Post-translational modifications of tau protein in Alzheimer\u2019s disease. J Neural Transm, 2005,112(6):813\u2013838","journal-title":"J Neural Transm"},{"issue":"3","key":"559_CR31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3233\/JAD-2009-1003","volume":"16","author":"X. Run","year":"2009","unstructured":"Run X, Liang Z, Zhang L, et al. Anesthesia induces phosphorylation of tau. J Alzheimers Dis, 2009,16(3): 619\u2013626","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"559_CR32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3233\/JAD-2009-1069","volume":"17","author":"Z. Liang","year":"2009","unstructured":"Liang Z, Liu F, Iqbal K, et al. Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis, 2009,17(3),531\u2013539","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"559_CR33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11596-010-0106-4","volume":"30","author":"H. Wang","year":"2010","unstructured":"Wang H, Zhao H, Ye Y, et al. Focal cerebral ischemia induces Alzheimer\u2019s disease-like pathological change in rats. J Huazhong Univ Sci Technol [Med Sci], 2010, 30(1):29\u201336","journal-title":"J Huazhong Univ Sci Technol [Med Sci]"},{"issue":"3","key":"559_CR34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF02829548","volume":"26","author":"J. Zhou","year":"2006","unstructured":"Zhou J, Chen J, Feng Y. Effect of truncated-ApoE4 overexpression on tau phosphorylation in cultured N2a cells. J Huazhong Univ Sci Technol [Med Sci], 2006,26(3):272\u2013274","journal-title":"J Huazhong Univ Sci Technol [Med Sci]"},{"issue":"6","key":"559_CR35","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/NEN.0b013e3181776293","volume":"67","author":"M. Tajes","year":"2008","unstructured":"Tajes M, Gutierrez-cuesta J, Folch J, et al. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J Neuropathol Exp Neurol, 2008,67(6):612\u2013623","journal-title":"J Neuropathol Exp Neurol"},{"issue":"43","key":"559_CR36","doi-asserted-by":"crossref","first-page":"18367","DOI":"10.1073\/pnas.0907652106","volume":"106","author":"K. Ghosal","year":"2009","unstructured":"Ghosal K, Vogt DL, Liang M, et al. Alzheimer\u2019s disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci USA, 2009,106(43):18367\u201318372","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"559_CR37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/35096075","volume":"2","author":"P. Cohen","year":"2001","unstructured":"Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol, 2001,2(10):769\u2013776","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"559_CR38","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1046\/j.1471-4159.2000.0721327.x","volume":"72","author":"G. Chen","year":"1999","unstructured":"Chen G, Huang LD, Jiang YM, et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem, 1999,72(3),1327\u20131305","journal-title":"J Neurochem"}],"container-title":["Journal of Huazhong University of Science and Technology [Medical Sciences]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-010-0559-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-010-0559-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-010-0559-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T04:29:39Z","timestamp":1559795379000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-010-0559-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1007\/s11596-010-0559-5","relation":{},"ISSN":["1672-0733","1993-1352"],"issn-type":[{"value":"1672-0733","type":"print"},{"value":"1993-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}